Abstract
For early-stage non–small-cell lung cancer (NSCLC), multimodality therapy is standard practice, but 5-year survival rates for stage II and III disease remain low (20%–40%). Molecular profiling has reshaped therapy in stage IV disease with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for EGFR -mutation patients. In addition, prior studies, specifically the 2006 IALT trial (N Engl J Med 2006; 355:983), demonstrated that high tumor levels of excision repair cross-complementation group 1 (ERCC1) immunohistochemistry (IHC) are predictive of cisplatin resistance. To assess the feasibility of using EGFR …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
